News | January 08, 2015

BioZorb Surgical Implant Improves Targeting of Radiation Therapy

Clinical trial recorded average radiation dose decrease of more than 50 percent

BioZorb, Focal Therapeutics, breast cancer, radiation dose, SIS World Congress

Image courtesy of Focal Therapeutics Inc.

January 8, 2015 — A new surgical device enables breast cancer patients to be treated with dramatically improved targeting of radiation. Findings were presented at the 18th SIS World Congress on Breast Healthcare. The congress was co-hosted by the Senologic International Society (SIS) and the American Society of Breast Disease (ASBD).

A detailed report headed up by Linda Ann Smith, M.D., breast surgeon at Comprehensive Breast Care in Albuquerque, N.M., describes the value of more accurately targeting the site of breast cancer removal. Smith and co-author Robert Kuske, M.D. documented clinical outcomes achieved when using the new BioZorb three-dimensional surgical implant from Focal Therapeutics Inc.  

Kuske, of Arizona Breast Cancer Specialists, is the pioneer of accelerated partial breast irradiation (APBI), a five-day alternative to conventional, more lengthy whole-breast irradiation for many early-stage breast cancer patients. BioZorb was used in combination with APBI for many patients in the study. 

In the 41 cases summarized in the report, the U.S. Food and Drug Administration (FDA)-cleared device assisted physicians in identifying with greater ease and precision the exact location in the breast that required radiation. The treatments are delivered after surgery in order to decrease the chances of cancer recurrence. Using the implant to visualize the site of breast tumor removal helped to define the radiation treatment volumes, and this resulted in an average decrease of 55 percent. The authors noted that having the implant helped to ensure that the appropriate amount of radiation was delivered to the proper location and it allowed them to confidently exclude radiation exposure to nearby normal tissue.

"To make sure breast cancer patients receive the most precise treatment possible with the lowest possible dose, the marking method must be clear and reliable from both the surgeon's and radiation oncologist's point of view," said Smith. "The marker we studied is well designed from both of these perspectives. It was easily implanted, using techniques that all surgeons know. It then remained in position and defined the site of tumor removal so that the radiation oncologist could precisely target the radiation."

The authors found that with the new three-dimensional marker device in place, they were able to more precisely prescribe the desired dose of radiation, regardless of which delivery method of radiation was prescribed for patients. 

Current methods for targeting radiation in the breast can overestimate the volume of tissue that needs treatment, which can lead to poor cosmetic results and inadvertent exposure of adjacent normal tissues to radiation. The device used in the current study is sutured directly to the tumor resection site, which helps to address these issues. Cosmetic results for patients implanted with the marker were noted to be excellent. In all patients, the BioZorb marker remained at the site of surgery with no evidence of migration and there were no infections or device-related complications.

The device's unique open-spiral design incorporates six permanent titanium clips in a fixed 3-D array and provides specific landmarks at the site of the excised tumor. This allows the surgeon to secure the device to adjacent tissue and use it for oncoplastic reconstruction prior to its use in radiation treatment planning. Oncoplastic surgery combines plastic surgery techniques with surgical oncology methods, to help maintain the treated breast's natural shape and contour.

The device has been used successfully in both the United States and New Zealand. It is made of a bioabsorbable material commonly used in other medical devices, allowing the patient's body to absorb the material slowly over time.

The findings of the study presented at the SIS World Congress are consistent with previous research presented at other conferences. The SIS meeting was held Oct. 16-19 in Orlando, Fla.

For more information: www.focalrx.com

Related Content

Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Feature | Breast Density | July 05, 2017 | By Nancy M. Cappello, Ph.D.
Two decades of research on the masking risk of dense breast tissue by mammography screening is indisputable. As the...
Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50
News | Mammography | June 30, 2017
June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the
GE Healthcare Announces First U.S. Installation of Senographe Pristina Mammography System
News | Mammography | June 29, 2017
GE Healthcare has collaborated with Boca Raton Regional Hospital (Boca Raton, Fla.) to bring a more comfortable...
Overlay Init